<img height="1" width="1" src="https://www.facebook.com/tr?id=414339248965737&amp;ev=PageView &amp;noscript=1">

Phase 1 Solutions 

Solutions built for the speed, volume, and precision of Phase 1 clinical trials.

With over 80% of US clinical trials failing to meet their patient enrollment timelines and an average of 30% of patients dropping out, point-of-need ophthalmic clinics are a game changer.

20/20 Onsite Clinical Trial Phase 1 Solutions

Phase 1 Solutions

The speed and complexity of Phase 1 trials can strain traditional solutions. As the only solutions provider solely dedicated to point-of-need ophthalmic assessments for clinical trials, 20/20 Onsite delivers embedded, trial-ready support that adapts to shifting schedules, high volumes, and strict data standards, all to protect your ocular endpoints.

Faster Timelines: Enroll patients up to 50% faster
Higher Data Quality: 98% data accuracy submission
Improved Retention: 70% reduction in patient dropout rates
Stronger Site Efficiency: 100% screening timelines met

Point of Need

100%

Screening timelines met across all business operations.

Data Integrity

98%

Data accuracy submission rate.

Patient Retention

91%

Patient retention rate vs industry standard 70%.

Patient Centricity

95+

Patient Net Promotor Score vs industry average NPS of 30-50.

20/20 Onsite Clinical Trial Phase 1 Solutions

How Phase 1 Is Unique

While the ophthalmic assessments themselves (e.g., OCT, VA, slit lamp) may not differ significantly across phases, the operational tempo and structure of Phase 1 trials are uniquely demanding:

  • Compressed Timelines: Assessments often occur at critical timepoints, such as Day -1, Day 1, and Day 8, requiring rapid scheduling flexibility.
  • High Tempo, High Volume: Sites run continuous patient cohorts with assessments every 5–10 minutes across long clinic days.
  • Single-Site Execution: Trials are often centralized at one Phase 1 unit and run for 3–12 months (typically ~6 months).
  • Frequent Workflow Adjustments: Assessment schedules change often; operational agility is critical.
  • Endpoint Protection: Every assessment must be tightly timed, consistent, and ready for central read.

20/20 Onsite Is Built for Phase 1

Phase 1 sites need a deeply integrated, high-performance partner for ocular assessments. 20/20 Onsite delivers:

  • On-Site Integration: We embed directly into your Phase 1 clinic or deploy our mobile suite, keeping assessments on schedule and location.
  • Clinic Day Design Expertise: We help structure the workflow for optimal patient throughput and assessment timing.
  • Unmatched Tempo Handling: We can run multiple “lanes” simultaneously to scale with any cohort size.
  • Supports Inclusion/Exclusion Decisions: Our baseline ophthalmic assessments help identify pre-existing conditions that may include or exclude participants from Phase 1 trials. 
  • Trial-Experienced Technicians: Our clinicians adapt quickly to changing timepoints, participants, and rescheduling needs. We bring consistent data quality and fluency in eSource platforms and regulatory requirements.
2020 Onsite Clinical Trial Phase 1 Solutions
2020 Onsite Clinical Trial Phase 1 Solutions

The 20/20 Onsite Advantage

Our seamlessly integrated phase 1 solutions help sites streamline patient flow, scale tempo, and deliver clean, timely data. Our ability to provide flexibility, structure, and full staffing makes 20/20 Onsite a competitive advantage that helps unlock Phase 1 revenue for our CRO partners.

For sponsors, 20/20 Onsite helps trials move faster, reduce risk, and obtain reliable early safety signals without the operational headaches that can occur with traditional setups.

Take a Tour

Tour our patient-centric, point-of-need Mobile Vision Clinic (MVC) and see how we accelerate clinical trials.

Clinical Trials Phase 1-3

Support for ophthalmic assessments or other study-specific eye-related solutions as part of a research protocol.

Post Marketing

Support for safety or surveillance ophthalmic assessments and eye-related clinical trial solutions for patients outside of a clinical protocol.

20/20 Onsite Ophthalmic assessments and eye-related clinical trial solutions - MVC

Mobile Vision Clinic

20/20 Onsite Ophthalmic assessments and eye-related clinical trial solutions - MVS

Mobile Vision Suite

20/20 Onsite Ophthalmic assessments and eye-related clinical trial solutions - MVP

Mobile Vision Pod

case_study

Applied Genetics Technology Company (AGTC) partners with 20/20 for their nationwide ophthalmic phase 1 and 2 clinical trials

press_release

Observational Study Confirms Eye Exams in Mobile Settings Have the Same Results as In-Office Exams

white_paper

Keeping Your Trials on Track: How Mobile Vision Clinics Are Making an Impact on Pre-screening, Screening and Retention

Meet 20/20 Onsite's Industry and Scientific Advisory Board

The Industry and Scientific Advisory Board (IASAB) meets quarterly to help identify patient needs, product opportunities, and market challenges associated with the provision of vision-related assessments for clinical trials and safety surveillance.

Rajat-Agrawal-Headshot
Rajat Agrawal, MD, MS

CEO and President Retina Global

Headshot-Jeanne
Jeanne Hecht, Chair

Founder and CEO JTH Consulting, LLC

Jeffrey-S.-Heier-Headshot
Jeffrey S. Heier, MD

Director of the Vitreoretinal Service and Director of Retina Research Ophthalmic Consultants of Boston (OCB)

Peter Kaiser Headshot-1
Peter K. Kaiser, MD

Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology Cleveland Clinic Lerner College of Medicine

Beth-Marsh-Headshot
Beth Marsh

Vice President of North America Sales and Marketing, Ophthalmology Apellis Pharmaceuticals

Jason-Menzo-Headshot
Jason Menzo

Chief Operating Officer Foundation Fighting Blindness

Adam-Ramsey-Headshot
Adam Ramsey, OD

Owner Socialite Vision

Medical-Solution-1

Click below to read more about each board member's commitment to research or submit a question to be asked during our next quarterly meeting.


Phase 1 Advantages

Faster Timelines

2020 Onsite Ophthalmic Clinical Trial Phase 1 Solutions

Our on-site integration eliminates off-site scheduling delays, helping sponsors hit aggressive enrollment and assessment schedules. 

Mobile Vision Clinics (MVCs) eliminate the need for patient travel. In one study, we eliminated the need for patients to travel 45 minutes each way for eye assessments, saving an estimated 5,130 minutes (85.5 hours) of participant travel time throughout the study.

Higher Data Quality

2020 Onsite Ophthalmic Clinical Trial Phase 1 Solutions

Trial-experienced technicians, standardized assessments, and eSource fluency mean clean, audit-ready data from Day 1, reducing rework, queries, and the risk of protocol deviations.

We fit seamlessly into your protocols’ scheduling windows. In one study, all eye exams had to occur from 7:00 am to 11:00 am. These controlled assessment conditions and rigorous protocols ensured high-quality data for analysis.

Retention & Site Efficiency

2020 Onsite Ophthalmic Clinical Trial Phase 1 Solutions

Participants stay on-site for all assessments, minimizing burden and drop-off. Our proven methods have been shown to decrease the patient dropout rate by 70% compared to the industry average.

By helping design and run efficient clinic days we improve throughput and ensure ophthalmic assessments never become bottlenecks. We can add multiple lanes to scale with the study requirements seamlessly.


20/20 Onsite vs Traditional Phase 1 Solutions

We’ve executed Phase 1 programs with some of the most trusted CROs in clinical research. We have established a reputation as the go-to partner for ophthalmic clinical trials.

Phase 1 Requirement

20/20 Onsite

Traditional Solutions

Compressed Timelines

Point-of-need/mobile setup enables rapid response to protocol-driven timepoints (i.e., Day -1, Day 1, Day 8 assessments)

Limited flexibility and availability due to current patient commitments for rapid turnaround

High Tempo, High Volume

Staffed for continuous cohort flow (i.e., multiple patients every 5-10 minutes), can scale lanes as needed

Not typically equipped for rapid-fire throughput or large volume

Embedded Execution

Fully embedded at site or mobile suite stationed nearby for extended periods

Off-site locations that can disrupt trial logistics and flow

Frequent Workflow Adjustments

Clinical staff adapt to dynamic schedules with minimal disruption

Fixed hours and scheduling rigidity can prevent quick changes

Protocol & Workflow Design Expertise

Consultative support during trial startup and clinic day design

Normally, no role in clinic design or protocol structuring

Experience with Trial Tools

Familiar with multiple eSource systems and compliance standards

Typically (not always) lacks experience with clinical data systems

Scalability Across Cohorts

Ability to scale the number of lanes available to support any cohort size

Capacity limited by clinic space and availability

20/20 Onsite Clinical Trial Solutions

The level of care that 20/20 Onsite provides to patients is outstanding in every way. The staff is professional, kind, and compassionate, and they are well-trained to handle any challenge that comes their way. I believe that mobile care is the cutting-edge of optometry, and I am honored to be a part of it. Dr. Keswani, OD
We recognize the incredible commitment patients make when they enroll in our trials and our goal is to match that commitment and support them in any way possible. By using a creative patient-focused approach to testing via 20/20 Onsite’s mobile vision testing program, we ‘take the test to the patient’ to support their needs during this extremely difficult time. Sue Washer, CEO, AGTC
While working with 20/20 Onsite for previous and current studies, we have been able to provide ophthalmological services that were previously not feasible for our clinical units. Doing so has been very successful in providing safety and ophthalmological oversight of study participants – as required by good clinical practices and the sponsor protocol. Dr. David Wyatt, Vice-President and Global Medical Lead, Syneos Health
It has been a pleasure to work with 20/20 Onsite. Your professionalism, attention to detail, and willingness to pivot or adjust to our sometimes fluid clinical trial protocol schedules has been such a blessing. We have certainly appreciated the opportunity to work with you; and anticipate future endeavors. Jerry Punch, MD. Co-Primary Investigator, Alliance for Multispecialty Research (AMR)

Phase 1 Case Studies

20/20 Onsite Clinical Trial Phase 1 Solutions

Streamlining a Phase 1 Study for Syneos Health

20/20 Onsite Clinical Trial Phase 1 Solutions

Enhancing Phase 1 Clinical Trials with Point-of-Need Safety Assessments

20/20 Onsite Clinical Trial Phase 1 Solutions

Optimizing Phase 1 Trials with the Mobile Vision Pod

20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients Vertex
20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients Biogen
20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients Syneos
20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients Pega
20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients AGTC
20/20 Onsite Point-of-need clinical trial ophthalmic assessments and solutions - Clients Blue Bird Bio

FAQs: 20/20 Onsite's Phase 1 Solutions

Book a call today to discuss phase 1 solutions from the only provider dedicated to point-of-need eye assessments for clinical research.

SIGN UP: EYES ON RESEARCH

Our newsletter dedicated to clinical research, insights on patient-centric treatments, and point-of-need clinical trial solutions.